EMA accepts Pfizer's axitinib for review in renal cell carcinoma
03 June 2011
Pial Ganguli
Please Login to read the full article.
03 June 2011
Pial Ganguli
Please Login to read the full article.
RELATED CONTENT
NEWS
- FDA reviewers question efficacy of Pfizer's kidney cancer drug ahead of ODAC
- US FDA accepts Pfizer's axitinib filing in renal cell carcinoma
- NICE plans appraisal for Pfizer's Inlyta in RCC where others have failed
- Pfizer's Torisel fails in Phase III second-line kidney cancer trial
ANALYSIS
Other Informa Analysis
EVENTS
07 June 2012
The Rembrandt Hotel, London
12 June 2012
Annecy, France
18 June 2012
Boston Convention & Exhibition Center, Boston, MA
JOB OF THE WEEK
Section Head (m/f)
DRA International/CIS Section
Section Head (m/f)
DRA International/CIS Section
